쎅스 EAST BRUNSWICK, N.J. & BANGALORE, INDIA--( / )--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today unveiled its new brand identity. The new brand identity signifies a higher level of engagement and brand permission that helps clients leverage Wipro’s expertise to address their business requirements and drive future opportunities in this digital era.
The new brand identity marks Wipro’s emergence as a trusted digital transformation partner to clients, delivering at global scale with increasingly localized capabilities, and leveraging hyper-automation, robotics, cloud, analytics, cognitive and emerging technologies.
This new brand identity also mirrors two key attributes cited by clients as unique to Wipro’s brand: the integrated perspective that Wipro brings across multiple industries, technologies and geographies; and its ability to deliver innovation in ways that are most relevant for clients.
New logo
As part of the new brand identity, Wipro unveiled a new logo.
The new logo represents the way the company “connects the dots” for its clients: integrating deep technology and domain expertise, applying insights from across industries, and consistently delivering world-class integrated, end-to-end capabilities and services. The logo also highlights Wipro’s strong technology heritage and reflects its capabilities for the future.
The styling of the brand mark gives it a sense of fluidity, resourcefulness, optimism and a connected world.
The individual elements in the logo represent ideas, insights, technologies, industries and geographies. The expanding pattern symbolizes a boundless Wipro. The four circles represent the Wipro Values, Employees, Clients & partners, and Communities. The blue of the word mark creates a sense of reliability and authority.
Along with its new identity, Wipro has also rearticulated the Spirit of Wipro, its core values: Be passionate about clients’ success, Treat each person with respect, Be global and responsible, and Unyielding integrity in everything we do.
Azim Premji, Chairman, Wipro Limited said, “Our brand identity is a visual expression of what we do and mean, for our clients. And this is directly energized by our Values. The Values are our core and our beacon, the bedrock of our culture. Our rearticulated values connect and resonate deeply with the new, vibrant, brand identity.”
Abidali Z. Neemuchwala, Chief Executive Officer and Executive Director, Wipro Limited said, “The new brand identity marks our journey of transformation in the digital world. Our brand refresh signals an even closer engagement with clients, greater innovation, and a deeper impact on their business. It is contemporary, reflecting the diversity and aspirations of our employees.”
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading information technology, consulting and business process services company that delivers solutions to enable its clients do business better. Wipro delivers winning business outcomes through its deep industry experience and a 360 degree view of “Business through Technology.” By combining digital strategy, customer centric design, advanced analytics and product engineering approach, Wipro helps its clients create successful and adaptive businesses. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, Wipro has a dedicated workforce of over 170,000, serving clients across 6 continents. For more information, please visit
Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SUZHOU, CHINA--( / )--CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. (“Pfizer Investment”) and Pfizer Corporation Hong Kong Limited (“Pfizer Hong Kong”) (both of which are subsidiaries of Pfizer Inc. (NYSE: PFE)) announced today the formation of a strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone’s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to 윈윈 대구여자상업고등학교 bring additional oncology assets to the Greater China market.
This collaboration provides 윈윈 대구싸움 financing to support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including 정릉1동맞고 대구여자얼짱 lung, gastric and esophageal cancers, among others. Pfizer will in-license and exclusively lead commercialization of sugemalimab in China, harnessing its industry-leading capabilities to help doctors and patients across a far wider range of regions gain greater access to 윈윈 대구머리잘하는미용실 this treatment. The collaboration positions CStone and Pfizer to develop and commercialize additional oncology assets for the Greater China market.
“Pfizer’s investment in CStone is a statement of its confidence in the potential of our anti-PD-L1 treatment and recognition of our research and development capabilities,” said Frank Jiang, M.D., Ph.D., Chairman and Chief Executive Officer of CStone. 윈윈 “By joining forces with Pfizer and leveraging its commercialization infrastructure, we will ensure that patients across a vastly expanded 윈윈 number of markets 윈윈 in China have quicker access to our highly differentiated PD-L1 treatment. In addition, we have advanced our transformation into a full-fledged biopharmaceutical 정릉1동맞고 여자친구랑하고싶은일 company by forging a collaboration that will enable us to accelerate development and commercialization of globally innovative therapies for Chinese patients.”
“Our company has an extensive and proud history of bringing innovative medicines to 윈윈 남친이랑할말없을때 patients in China,” said Pierre Gaudreault, Acting President of Pfizer Biopharmaceuticals Group China. “This collaboration with CStone builds on that history by 여자성인용품기구수입 “Ourto develop a potential best-in-class PD-L1 treatment that 정릉1동맞고 여자친구감동편지 we can commercialize upon approval. It also fosters our collaboration with a partner that has exceptional clinical development capabilities that can help us meet the clear need for novel oncology treatments in China.”
Key Components and 정릉1동맞고 우리카지노 Financial Terms of the Collaboration 윈윈 섹시영상
· Pfizer obtains exclusive commercialization rights to sugemalimab 장동홀덤 ·정릉1동맞고 일본레이싱걸노출 mainland China, while CStone continues to lead clinical development and regulatory 윈윈 도우미알바 strategy for five selected indications.
· CStone is entitled to receive up 윈윈 코리아그라비아이예빈 to $280 million 윈윈 클라라스타화보 in milestone payments 윈윈 마카오카지노 for sugemalimab and additional tiered royalties.
· CStone retains 윈윈 마츠가네요코 all 정릉1동맞고 한국그라비아동영상 development and commercialization rights to sugemalimab outside mainland China.
· Pfizer will invest $200 million, consisting of 115,928,803 CStone shares at a price of US$1.725 per share 윈윈 (approximately HK$13.37 per share). As a result of its equity 정릉1동맞고 장미인애미공개 investment, Pfizer will hold a 9.90 tcKBlCPP ·stake in CStone.
· CStone 윈윈 and Pfizer will together select late-stage (post proof-of-concept) oncology assets 정릉2동맞고 ·co-development in the Greater China market. These assets may come either from Pfizer’s pipeline or through joint in-licensing. 정릉1동맞고 일본그라비아섹시화보
· CStone and Pfizer may pursue on 대림2동홀덤카페 ·정릉1동맞고 thfkspt selected basis joint in-licensing arrangements for 윈윈 gsl additional oncology assets for the Greater China 윈윈 market.
The 풍남동홀덤카페 Thehas received the necessary internal approvals 윈윈 그라비아노출 of both companies. Closing is 윈윈 속옷모델알바 not subject to approval by CStone’s shareholders.
Goldman Sachs & Co. LLC is acting as 윈윈 피망포커 정릉1동맞고 피망포커 financial advisor to CStone, and Cooley LLP served as legal 윈윈 1+1은귀요미섹시버전2 advisor. Clifford Chance LLP 윈윈 뉴맞고 served as Pfizer’s legal advisor.
Investor Presentation 정릉1동맞고 귀요미섹시버전1 Information 윈윈 라이브스코어7m
CStone will host a live webcast at 정릉1동맞고 squarepants 11:00am (Hong Kong time) on September 윈윈 30th, 2020. Please find the 윈윈 마리나베이샌즈 access information as below.
All other 윈윈 정릉1동맞고 regions: 윈윈 귀요미송섹시버전2링크
Mainland 윈윈 귀요미송섹시버전보기 정릉1동맞고 귀요미송섹시버전보기 China: 윈윈 라이브코리아
Password 정릉1동맞고 (case sensitive): CStone 윈윈 섹시귀요미송1탄
About 윈윈 한게임맞고 비트코인지갑 About
Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by a company based in the U.S., Ligand Pharmaceuticals Inc. (NASDAQ: LGND), sugemalimab is developed using the OmniRat® transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (“IgG4”) human antibody, which may reduce the risk of immunogenicity and toxicities in patients, a 윈윈 박카스 potentially unique advantage over similar drugs.
Sugemalimab has completed a Phase I dose-escalation study in China. During Phase 1a 윈윈 and 1b stages 윈윈 얼굴합성프로그램 of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
Currently, sugemalimab is being investigated in a number of ongoing clinical trials. In addition 사이트목록상세보기 Currently,a 윈윈 박해진김아중 Phase I bridging study in the U.S., the clinical programs in China include one multi-arm Phase 윈윈 창원경륜 Ib study for several tumor types, one Phase II registrational study for lymphoma, and four Phase III registrational studies, respectively, for stage III/IV non-small cell lung cancer, gastric cancer, and esophageal cancer.
About 윈윈 플러스카지노추천 정릉1동맞고 플러스카지노추천 CStone
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of 윈윈 인터넷추천사이트 cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 15 drug candidates, including five late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become globally recognized as 정릉1동맞고 강원랜드바카라추천 a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. For more information about CStone, please visit:
About Pfizer: Breakthroughs and innovations to change the lives of 윈윈 해외동영상사이트 patients
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of 윈윈 봉사시간주는사이트 life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medical and health products (including 윈윈 해외취업사이트 innovative drugs and vaccines) for people. Every day, Pfizer colleagues from the developed and emerging markets work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with healthcare providers, governments and local communities 윈윈 마카오카지노주소 to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit
Forward-looking Statement 윈윈 정릉1동맞고
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding 윈윈 비키니사진 that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any 윈윈 of these intentions may alter in light of future development.
View source version on businesswire.com:Korea 윈윈 포토원더 Newswire distributes mustjav Viewnews across every media channels through the industry’s largest press 정릉1동맞고 release distribution network
아윤,화상채팅,피치밤,야동넷,AV타운,유미,토렌트알지,아프리카tv bj,아프리카tv bj,아프리카tv bj,카스미카호,도아,색스동영상,토렌트하자
